Table 1. Demographic characteristics and clinical features of controls, pre-manifest and stage II/III HD cohorts.
Data presented as median (range).
| Disease stage | Controls | Pre-manifest HD | Stage II/III HD |
|---|---|---|---|
| Number of subjects | 15 | 14 | 13 |
| Age | 54 (29–69) | 45 (31–58) | 58 (42–70) |
| Female: Male | 6:9 | 9:5 | 5:8 |
| BMI | 25 (20–37) | 27 (23–39) | 26 (20–33) |
| CAG | - | 42 (40–47) | 42 (42–47) |
| Disease burden score | - | 299 (207–434) | 410 (273–702) |
| Functional Assessment | 25 | 25 (21–25) | 21 (11–24) |
| UHDRS Total Functional Capacity | 13 | 13 (12–13) | 9 (5–12) |
| UHDRS Motor Score | 0 | 0 (0–11) | 38 (10–65) |
| STECN | 82 (60–93) | 71 (47–91) | 45 (30–81) |
| STEWR | 100 (83–102) | 96 (64–110) | 57 (37–100) |
| STEI | 45 (29–68) | 42 (34–52) | 24 (20–44) |
| SDT | 51 (42–65) | 52 (37–62) | 31 (17–50) |
| VFT | 48 (30–66) | 41 (26–70) | 27 (12–58) |
| CS | 322 (276–359) | 298 (225–369) | 182 (133–308) |
| PBA | 2 (0–10) | 8 (2–31) | 21 (5–55) |